Melatonin is effective in treating sleep problems in Angelman syndrome but problems in metabolising melatonin may be part of the Angelman phenotype

Authors: Braam, W.1; Smits, M. G.2; Didden, R.3; Curfs, L. M. G.4

Source: Journal of Intellectual Disability Research, Volume 52, Number 10, October 2008 , pp. 814-814(1)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Background: Sleep problems are frequent in Angelman syndrome and often severe. Previous studies suggested that melatonin improves sleep in insomniac patients with Angelman syndrome. Method: We performed a randomized placebo-controlled study in eight children with Angelman syndrome with chronic insomnia. Patients received, depending on age, either melatonin 5 or 2.5 mg, or placebo. Parents recorded lights off time, sleep onset, night wakes, wake-up time and epileptic seizures in a diary. After the 4-week placebo controlled phase of the study, all patients received 4 weeks open treatment with melatonin. We present data on these eight patients and 20 new AS patients that we treated in our clinic and did not describe in this study. Results: In our randomized study melatonin significantly advanced sleep onset by 28 min., decreased sleep latency by 32 min., increased total sleep time by 56 min., reduced the number of nights with wakes from 3.1 to 1.6 nights a week. After 4 weeks of open treatment however, there was in some patients a tendency to a reduction in therapeutic gain. Salivary endogenous melatonin levels, measured at baseline and at the last evening of the fourth treatment week when no study medication was taken, showed a marked increase. In AS patients in whom the melatonin lost its effect, melatonin levels had become extremely high, whereby the normal 24h melatonin rhythm was lost. Discussion: Four weeks of melatonin treatment in Angelman syndrome children with chronic insomnia was more effective in decreasing sleep latency, advancing sleep onset, reducing number of night wakes and increasing total sleep time than placebo. However, after several weeks melatonin lost its beneficial effect in most AS patients. We found indications that melatonin metabolism in AS is disturbed and that this possibly is part of the AS phenotype.

Keywords: Angelman syndrome; melatonin; sleep problems

Document Type: Research article

DOI: 10.1111/j.1365-2788.2008.01119_11.x

Affiliations: 1: Heeren Loo Zuid, Wekerom 2: Gelderse Vallei Hospital, Ede 3: Radboud University, Nijmegen/Trajectum, Zutphen 4: Department of Clinical Genetics, Academic Hospital Maastricht/University Maastricht, the Netherlands

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.39 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A